Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

BARDA Collaborates with DiaSorin, Mesa Biotech to Develop COVID-19 Rapid Diagnostics

by Global Biodefense Staff
March 24, 2020
Artificial Intelligence and Big Data Analytics for Biodefence: Implications for Threat Assessment And Biosurveillance

Credit: Global Biodefense

The U.S. Department of Health and Human Services (HHS) this week announced additional actions to support the development of a novel coronavirus diagnostics.

The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), will provide Mesa Biotech with technical expertise and up to $561,330 in immediate funding in support of its novel coronavirus disease (COVID-19) diagnostic test.

This funding from BARDA will support the development efforts required for Mesa Biotech to submit a request to the U.S. Food and Drug Administration (FDA) for potential Emergency Use Authorization (EUA) of the Accula COVID-19 point-of-care test.

The Accula COVID-19 test will leverage Mesa Biotech’s Accula Dock instrument that has been 510(k)-cleared and Clinical Laboratory Improvement Amendments (CLIA)-waived by the FDA for influenza point-of-care testing. Utilizing the Accula Dock, the new Accula COVID-19 test will provide molecular results for COVID-19 within 30 minutes from throat, nasal, or nasopharyngeal swab samples. The diagnostic test is intended for use in clinical and hospital laboratories. BARDA continues to work with its industry partners to develop rapid diagnostic tests for COVID-19.

DiaSorin Molecular, LLC of Cypress, California will also receive BARDA’s technical assistance and $697,000 for the development of the Simplexa™ COVID-19 Direct assay, a molecular test for qualitative identification of the novel coronavirus SARS-CoV-2 which causes COVID-19.

DiaSorin received Emergency Use Authorization (EUA) from the FDA on March 19 for their COVID-19 Direct kit. DiaSorin will begin shipping kits for immediate use in laboratories across the US this week.

DiaSorin’s test will use a nasopharyngeal (back of the nose and throat) swab from patients and is designed for use with the company’s Simplexa™ Direct technology, a diagnostic platform currently used for their influenza and Respiratory Syncytial Virus (RSV) tests that have been cleared by the FDA.

The COVID-19 test would run on DiaSorin’s LIAISON® MDX instrument, which works in conjunction with LIAISON® MDX Studio software not only in reference laboratories, but also in labs that are closer to the patient, such as hospital labs. This technology uses a sample-to-answer approach with minimal operator input, yielding results in about 90 minutes. Hundreds of the company’s diagnostic devices are in use in large commercial, hospital, and public health laboratories around the country.

Sources: Medicalcountermeasures.gov, HHS.gov, FDA.gov

Tags: ASPRBARDACOVID-19HHSMagazine Edition 11 April 2020Rapid DiagnosticsSARS-CoV-2

Related Posts

New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy